| Literature DB >> 33897320 |
Ahmed Farhan1, Bader Alsuwayt2, Farhan Alanazi3, Abdulhadi Yaseen2, Mohamed A Ashour4.
Abstract
OBJECTIVE: Burn injuries are among the most common accidental health problems worldwide, frequently leading to health and socio-economic challenges. Despite this, no standard protocol for managing burn injuries can overcome the adverse effects of currently used drugs. The present study sets out to develop and evaluate the efficacy of new herbal ointments in providing synergistic anti-inflammatory, antimicrobial, antioxidant, and cell-proliferating activities. It also investigates the high-performance liquid chromatography (HPLC) characterisation of these new herbal ointments.Entities:
Keywords: Alkanna tinctoria; Burn; Calendula tripterocarpa; Matricaria aurea; Myrrh
Year: 2020 PMID: 33897320 PMCID: PMC8046957 DOI: 10.1016/j.jtumed.2020.10.023
Source DB: PubMed Journal: J Taibah Univ Med Sci ISSN: 1658-3612
Prescriptions for the pharmaceutical formulation of the new herbal ointments.
| Ingredient | 2.5% ointment (Amount in g) | 5% ointment (Amount in g) | 10% ointment (Amount in g) |
|---|---|---|---|
| 1.5 | 3 | 6 | |
| 1.5 | 3 | 6 | |
| 1.5 | 3 | 6 | |
| 0.75 | 1.5 | 3 | |
| Myrrh (solid tears) | 2.25 | 4.5 | 9 |
| Dist H2O | 10 | 20 | 30 |
| White soft paraffin | 247.5 | 225 | 190 |
| Liquid paraffin | 30 | 30 | 30 |
Results of the organoleptic and quality-control tests of the herbal ointments.
| Evaluation parameters | 2.5% ointment | 5% ointment | 10% ointment |
|---|---|---|---|
| Colour | Light green | Green | Green |
| Odour | Characteristic Rosemary odour | Characteristic Rosemary odour | Characteristic Rosemary odour |
| Consistency | Soft semisolid | Soft semisolid | Soft semisolid |
| Phase separation | Nil | Nil | Nil |
| Texture | Smooth | Smooth | Smooth |
| pH | 6.15 | 6.14 | 6.09 |
| Homogeneity | Homogenous | Homogenous | Homogenous |
| Loss on drying | 3.83% | 7.51% | 11.35% |
| Topical sensitivity test | No allergic reactions | No allergic reactions | No allergic reactions |
Average wound areas in mm/rat ± SE and wound-contraction percentages.
| Group | I | II | III | IV | V | VI |
|---|---|---|---|---|---|---|
| Average wound area in mm2/rat ± SE (% contraction) | ||||||
| Day 0 | 1104 ± 8.9 (0.0) | 1053 ± 12.02 (0.0) | 1086 ± 12.73 (0.0) | 1098 ± 18.77 (0.0) | 1072 ± 19.29 (0.0) | 1084 ± 12.99 (0.0) |
| Day 3 | 1097 ± 23.36 (0.63) | 1047 ± 27.11 (0.57) | 1057 ± 29.04 (2.67) | 1045 ± 25.57 (4.83) | 998 ± 32.21 (6.90) | 1025 ± 26.59 (5.44) |
| Day 6 | 992 ± 22.49 (10.15) | 970 ± 22.68 (7.88) | 988 ± 26.43 (9.02) | 887 ± 26.8 (19.22) | 753 ± 17.92 (29.76) | 845 ± 25.88 (22.05) |
| Day 9 | 882 ± 27.84 (20.11) | 841 ± 21 (20.13) | 905 ± 14.56 (16.67) | 832 ± 11.82 (24.23) | 676 ± 14.38 (36.94) | 766 ± 12.15 (29.34) |
| Day 12 | 821 ± 31.24 (25.63) | 743 ± 19.81 (29.44) | 772 ± 14.06 (28.91) | 431 ± 12.15 (60.75) | 361 ± 12.96 (66.32) | 427 ± 12.51 (60.61) |
| Day 15 | 769 ± 41.26 (30.34) | 665 ± 13.81 (36.85) | 623 ± 16.16 (42.63) | 204 ± 9.78 (81.42) | 131 ± 9.34 (87.78) | 218 ± 13.56 (79.89) |
| Day 18 | 749 ± 33.04 (32.16) | 418 ± 16.11 (60.30) | 302 ± 16.44 (72.19) | 99 ± 14.25 (90.98) | 52 ± 12.55 (95.15) | 96 ± 14.99 (91.14) |
| Day 21 | 685 ± 40.43 (37.95) | 215 ± 24.83 (79.58) | 176 ± 22.65 (83.79) | 45 ± 12.02 (95.90) | 18 ± 6 (98.32) | 31 ± 9.7 (97.14) |
Figure 1The histopathology of the skin at the 21st day of treatment, stained with haematoxylin-eosin stain. The skin of the non-treated group (Group I) shows ulceration and oedema, an abundance of mononuclear inflammatory cells, and early epithelialisation and granulated tissue. The skin of Group II shows an incomplete epidermal layer, the presence of oedema, and an abundance of mononuclear inflammatory cells with granulated tissue. The skin of Group III shows and almost complete hypertrophic epidermal layer and the presence of oedema and inflammation. The skin of Groups IV, V, and VI showed healed skin structures and complete epithelialisation; the layers of epidermis and dermis are as normal as unburned skin. Numerous hair follicles and sweat glands can be seen, along with adnexa restoration and extensive fibrosis and collagen tissue within the dermis.
Antimicrobial activities (expressed in mms of inhibition zone) against a range of pathogenic microorganisms.
| Test microorganisms | II | III | IV | V | VI | Control |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | 20 | |
| 8 | NA | 8 | 8 | 11 | 15 | |
| 8 | NA | NA | NA | 8 | 24 | |
| 10 | NA | NA | NA | NA | 26 | |
| 13 | NA | NA | NA | 9 | 27 | |
| 11 | NA | NA | NA | NA | 30 |
RCMB: Regional Center for Mycology and Biotechnology.
NA = No significant activity.
Figure 2Magnified section of the HPLC chromatogram of the herbal ointment at 254 nm, showing characteristic peaks that correspond to different phytoconstituents.
HPLC characterisation of different phytoconstituents in ointment preparation (5%) and their occurrence in each plant extract.
| Peak no. | R. time | % Area | C. tryp. | Rosemary | Alkanna | Myrrh | |
|---|---|---|---|---|---|---|---|
| 1 | 9.696 | 1.3 | ∗ | ∗ | ∗ | ||
| 2 | 10.382 | 0.49 | ∗ | ||||
| 3 | 10.640 | 0.48 | ∗ | ∗ | |||
| 4 | 11.555 | 0.51 | ∗ | ∗ | |||
| 5 | 12.900 | 6.45 | ∗ | ∗ | ∗ | ∗ | |
| 6 | 13.104 | 0.37 | ∗ | ||||
| 7 | 13.270 | 0.72 | ∗ | ||||
| 8 | 13.661 | 3.73 | ∗ | ∗ | ∗ | ||
| 9 | 14.105 | 0.86 | ∗ | ∗ | |||
| 10 | 14.508 | 2.52 | ∗ | ∗ | |||
| 11 | 14.923 | 2.63 | ∗ | ∗ | |||
| 12 | 15.189 | 11.21 | ∗ | ∗ | ∗ | ||
| 13 | 15.515 | 35.49 | ∗ | ∗ | ∗ | ||
| 14 | 15.922 | 4.90 | ∗ | ∗ | ∗ | ||
| 15 | 16.123 | 1.70 | ∗ | ∗ | |||
| 16 | 16.569 | 1.05 | ∗ | ∗ | |||
| 17 | 16.914 | 0.72 | ∗ | ∗ | |||
| 18 | 19.433 | 1.81 | ∗ | ∗ | ∗ | ||
| 19 | 19.876 | 1.91 | ∗ | ∗ | ∗ | ||
| 20 | 20.033 | 2.17 | ∗ | ||||
| P# | 20.144 | 4.50 | ∗ | ∗ | ∗ | ∗ | ∗ |
| 21 | 20.522 | 1.55 | ∗ | ||||
| 22 | 20.701 | 2.49 | ∗ | ∗ | |||
| 23 | 21.376 | 8.52 | ∗ | ||||
| P# | 21.634 | 2.19 | ∗ | ∗ | ∗ | ∗ | ∗ |
∗ = presence of the phytoconstituent in the sample.
P# = phthalates (plasticisers), i.e. solvent impurities.
Figure 3Wound contraction and the gross appearance of scald wound in all groups.
Figure 4Burn-wound area in relation to days of treatment.